Immune thrombocytopenic purpura

Platelets

Volumn , Issue , 2007, Pages 831-845

  Bussel, James B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46049105858     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50808-9     Document Type: Chapter

References (119)

1. Harrington W.J., Minnich V., Hollingsworth J.W., et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951, 38:1.
2. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981, 304:1135-1147.
3. George J.N., Woolf S.H., Raskob E., et al. Idiopathic thrombocytopenic purpura: The recommendations of the American Society of Hematology. A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
4. Bussel, J. B., & Cines, D. (in press). Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia and post-transfusion purpura. Hematology: Basic principles and practice (4th ed). In R. Hoffman, E. J. Benz, S. Shattil, B. Furie, H. J. Cohen, & L. E. Silberstein (Eds.), Churchill-Livingston.
5. Cines D., Blanchette V. Immune thrombocytopenic purpura. N Engl J Med 2002, 346:995-1008.
6. Drachman J.G. Inherited thrombocytopenia: When a low platelet count does not mean ITP. Blood 2004, 103:390-398.
7. Cines D.B., Bussel J.B., McMillan R.B., et al. Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program) 2004, 390-406.
8. Branehog I., Kutti J., Weinfeld A. Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 1974, 27:127-143.
9. Harker L.A. Thrombokinetics in idiopathic thrombocytopenic purpura. Br J Haematol 1970, 19:95-104.
10. Emmons R.V., Reid D.M., Cohen R.L., et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996, 87:4068-4071.
11. Kappers-Klunne M.C., de Haan M., Struijk P.C., et al. Serum thrombopoietin levels in relation to disease status in patients with immune thrombocytopenic purpura. Br J Haematol 2001, 115:1004-1006.
12. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and puri- fied ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
13. McMillan R., Wang L., Tomer A., et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004, 103:1364-1369.
14. Houwerzijl E.J., Blom N.R., van der Want J.J., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004, 103:500-506.
15. Cortelazzo S., Finazzi G., Buelli M., et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991, 77:31-33.
16. Schattner E., Bussel J.B. Mortality in immune thrombocytopenic purpura: Report of seven cases and consideration of prognostic indicators. Am J Hematol 1994, 46:120-126.
17. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
18. Arnott J., Horsewood P., Kelton J.G. Measurement of platelet-associated IgG in animal models of immune and non thrombocytopenia. Blood 1987, 69:1294-1299.
19. Cines D., Bussel J. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005, 106:2244-2251.
20. BaIlem P.J., Segal G.M., Stratton J.R., et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenia of both impaired platelet production and increased platelet clearance. J Clin Invest 1987, 80:33-40.
21. Gernsheimer T., Stratton J., Ballem P., et al. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Eng J Med 1989, 320:974-980.
22. Hersh J. Mathematical analysis of the relative contributions of decreased production-a peripheral destruction in idiopathic thrombocytopenic purpura and implication. J Theor Biol 2000, 203:153-162.
23. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000, 37:261-266.
24. Buchanan G.R. The nontreatment of childhood idiopathic thrombocytopenic purpura. Eur J Pediatr 1987, 146:107-112.
25. Simpson K.N., Coughlin C.M., Eron J., et al. Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Sem Hematol 1998, 35(Suppl 1):58-64.
26. Erederiksen H., Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999, 94:909-913.
27. Neylon A.J., Saunders P.W.G., Howard M.R., et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br J Haematol 2003, 122:966-974.
28. Aledort L.M., Hayward C., Chen M.G., et al. Prospective screening of 205 patients with ITP including diagnosis, serological markers, and the relationship of platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004, 76:205-213.
29. Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000, 160:1630-1638.
30. Kojouri K., Vesely S.K., Terrell D.R., et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104:2623-2634.
31. Schwartz J., Eldor A., Gillis A., et al. Long-term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003, 72:94-98.
32. Mayer J.L., Beardsley D.S. Varicella-associated thrombocytopenia: Autoantibodies against platelet surface glycoprotein V. Pediatr Res 1996, 40:615-619.
33. Semple J., Allen D., Hoggarth M., et al. In vivo actions of anti-D in children with chronic autoimmune thrombocytopenic purpura (AITP). Blood 1998, 92(10)(Suppl 1):720. [abstract].
34. Cooper, N., & Bussel, J. B. (in press). The pathogenesis of ITP. Br J Haematol.
35. Rajan S.K., Liebman H.A. Treatment of hepatitis C-related thrombocytopenia with interferon á. Blood 2000, 96(11):1090. [abstract].
36. Rajan S.K., Espina B.M., Liebman H.A. Hepatitis C virus-related thrombocytopenia: Clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 2005, 129:818-824.
37. Levy A.S., Bussel J. Immune thrombocytopenic purpura: Investigation of the role of cytomegalovirus infection. Br J Haematol 2004, 126:622-623.
38. Calleja E., Klein R., Bussel J. Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1?. Am J Hematol 1999, 61:94-97.
39. Franchini M., Veneri D. Helicobacter pylori infection and immune thrombocytopenic purpura: An update. Helicobacter 2004, 9:342-346.
40. Bussel J.B., Ostrow A., Segal J.B. Response to treatment of helicobacter pylori in patients with immune thrombocytopenic purpura: A systematic review and metaanalysis. Blood 2005, 106:2151.
41. Gasbarrini A., Francechi F., Tartaglione R., et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998, 352:878.
42. Emilia G., Longo G., Luppi M., et al. Helicobacter pylori edication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001, 97:812-814.
43. Lingwood C.A. Glycolipid receptors for verotoxin and helicobacter pylori: Role in pathology. Biochim Biophys Acta 1999, 1455:375-386.
44. Kiehl L.F., Ketchum L.H. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red aplasia, and autoimmune thrombocytopenia. Sem Oncol 1998, 25:80-97.
45. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency: Clinical and immunological features of 248 patients. Clin Immun 1999, 92:34-48.
46. Khalifa A.S., Take H., Cejka J., et al. Immunoglobulins in acute leukemia in children. J Pediatr 1974, 85:788-791.
47. Bussel J., Morell A., Skvaril F. IgG2 deficiency in autoimmune cytopenias. Monographs in Allergy 1986, 20:116-118.
48. Roark J.H., Bussel J.B., Cines D.B., et al. Genetic analysis of autoantibodies in ITP reveals evidence of clonal expansion and somatic mutation. Blood 2002, 100:1388-1398.
49. Pinchas-Hamiel O., Mandel M., Engelberg S., et al. Immune hemolytic anemia, thrombocytopenia and liver disease in a patient with DiGeorge syndrome. Isr J Med Sci 1994, 30:530-532.
50. Drappa J., Vaishnaw A.K., Sullivan K.E., et al. Fas gene mutation in the Canale-Smith syndrome, and inherited lymphoprofilerative disorder associated with autoimmunity. N Engl J Med 1996, 335:1643-1649.
51. Straus S.E., Lenardo M., Puck J.M., et al. The Canale-Smith syndrome. N Engl J Med 1997, 336:1457-1458.
52. el-Khateeb M.S., Awidi A.S., Tarawneh M.S., et al. HLA antigens, blood groups and immunoglobulin levels in idiopathic thrombocytopenic purpura. Acta Haematol 1986, 76:110-114.
53. Helmerhorst F.M., Nijenhuis L.E., de Lange G.G., et al. HLA antigens in idiopathic thrombocytopenic purpura. Tissue Antigens 1982, 20:372-379.
54. Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. J Clin Invest 1998, 102:1393-1402.
55. Posnett D.N., Gottlieb A., Bussel J.B., et al. T cell antigen receptors in autoimmunity. J Immunol 1988, 141:1963-1969.
56. Fogarty P.F., Rick M.E., Zeng W., et al. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exper Immunol 2003, 133:461-466.
57. Englehard D., Warner J.L., Kapoor N., et al. Effect of intravenous immune globulin on natural killer cell activity: Possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr 1986, 108:77-81.
58. Navratil I.S., Korb L.C., Ahearn J.M. Systemic lupus erythematosus and complement deficiency: Clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology 1999, 42:47-52.
59. Cooper N., Heddle N., de Haas M., et al. IV anti-D and IVIG achieve acute platelet increases by different mechanisms: Modulation of cytokine and platelet responses to IV anti-D by FcgRIIa and FcgRIIIa polymorphisms. Br J Haematol 2004, 124:511-518.
60. Brashem-Stein C., Nugent D.J., Bernstein I.D. Characterization of an antigen expressed on activated human T cells and platelets. J Immunol 1988, 40:2330-2333.
61. Calpin C., Dick P., Poon A., et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia?. Arch Ped Adol Med 1998, 152:345.
62. Yenicesu I., Sanli C., Gurgey A. Idiopathic thrombocytopenic purpura in acute lymphocytic leukemia. Pediatr Hematol Oncol 2000, 17:719-720.
63. Emmons R.V., Reid D.M., Cohen R.L., et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996, 87:4068-4071.
64. Rinder H.M., Munz U.J., Ault K.A., et al. Reticulated platelets in the evaluation of thrombopoietic disorders. Arch Pathol Lab Med 1993, 117:606-610.
65. Michel M., Kreidel F., Chapman E.S., et al. Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. Haematologica 2005, 90:1715-1716.
66. Beer J.H., Buchi L., Steiner B. Glycocalicin: A new assay - the normal plasma levels and its potential usefulness in selected diseases. Blood 1994, 83:691-702.
67. Cooper N., Woloski B.M.R., Fodero E.M., et al. Does treatment with intermittent infusions of IV anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura (ITP) to avoid splenectomy?. Blood 2002, 99:1922-1927.
68. Bussel J.B., Goldman A., Imbach P., et al. Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin. J Pediatr 1985, 106:886.
69. Bussel J.B., Graziano J.N., Kimberly R.P., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood 1991, 77:1884-1893.
70. Newman G.C., Novoa M.V., Fodero E.M., et al. A dose of 75 ug/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001, 112:1076-1078.
71. Niessner H., Clemetson K.J., Panzer S., et al. Acquired thrombasthenia due to GPIIb-Illa-specific platelet autoantibodies. Blood 1986, 68:571-586.
72. Rodgers R.P., Levin J. A critical reappraisal of the bleeding time. Sem Thromb Hemost 1990, 16:1-20.
73. Woerner S.J., Abildgaard C.F., French B.N. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics 1981, 67:453-460.
74. Buchanan G.R., Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002, 141:683-688.
75. Bussel J.B., Szatrowski T.P. Uses of intravenous gammaglobulin in immune hematologic disease. Immunol Invest 1995, 24:451-456.
76. Andersen J.C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994, 330:1560-1564.
77. Cheng Y., Wong R.S., Soo Y.O., et al. Initial treatment of immune thrombocytopenic purpura with highdose dexamethasone. N Engl J Med 2003, 349:831-836.
78. Bussel J.B. Another interaction of the FcR system with IVIG. Thromb Haemost 2002, 88:890-891.
79. Blanchette V., Imbach P., Andrew M., et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994, 334:703-707.
80. Newman G.C., Novoa M.V., Fodero E.M., et al. A dose of 75 ug/kg/d of IV anti-D increases the platelet count more rapidly and for a longer period of time than 50 ug/kg/d in adults with immune thrombocytopenic purpura. Brit J Haematol 2001, 112:1076-1078.
81. Tarantino, M. D., Young, G., Bertolone, S. J., et al. (in press). A single dose of anti-D immune globulin at 75 μg/kg is as effective as IVIg at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura (ITP) in children. J Pediatr.
82. Gaines A.R. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following RH0(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000, 95:2523-2529.
83. Scaradavou A., Woo B., Woloski B.M.R., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood 1997, 89:2689-2700.
84. Gaines A.R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglbinuria following RH0(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005, 106:1532-1537.
85. Medeiros D., Buchanan G.R. Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and long-term outcome. J Pediatr 1998, 133:334-339.
86. Gururangan S., Bussel J.B. Combination immunotherapy for patients with refractory ITP or Evan's syndrome (ES) [abstract]. Blood 1998, 92(suppl 1):3345.
87. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484.
88. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
89. Bussel J.B., George J.N., Kuter D.J., et al. An open-label, dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG531) in thrombocytoepnic adult patients with immune thrombocytopenic purpura (ITP). Blood 2003, 102:293.
90. Kuter D., Bussel J.B., Aledort L.M., et al. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients with immune thrombocytopenic purpura (ITP). Blood 2004, 104:511.
91. Bussel J.B., Kuter D.J., George J.N., et al. Longterm dosing of AMG531 is effective and well-tolerated in thrombocytopenic patients with immune thrombocytopenic purpura. Blood 2005, 106:220.
92. Jenkins J., Nicholl R., Williams D., et al. An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. Blood 2004, 104:2916.
93. McMillan, R., Bussel, J. B., George, J. N., et al. (in press). Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. N Engl J Med.
94. Kakumitsu H., Kamezaki K., Shimoda K., et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res 2005, 29:761-769.
95. Wang J., Wiley J., Luddy R., et al. Chronic immune thrombocytopenia purpura (ITP) in children: Assessment of rituximab treatment. J Pediatr 2005, 146:217-221.
96. Bennett C.M., Rogers Z.R., Kinnamon D.D., et al. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2005, (doi 10.1182/Blood-2005-08-3518.).
97. George J.N., Raskob G.E., Vesely S.K., et al. Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003, 74:161-169.
98. McMillan R., Bussel J.B., George J.N., et al. Selfreported health-related quality of life in adults with chronic immune thrombocytopenic purpura 2006, Manuscript submitted.
99. Simpson K.N., Coughlin C.M., Eron J., et al. Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D intravenous. Sem Hematol 1998, 35:58-64.
100. Schneider P., Wehmeier A., Schneider W., et al. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997, 337:1087-1089.
101. Bussel J.B., Kaufmann C.P., Ware R.E., et al. Do the acute platelet responses of patients with immune thrombocytopenic purpura to anti-D and to IV gammaglobulin predict response to subsequent splenectomy. Am J Hematol 2001, 67:27-33.
102. Scaradavou A., Bussel J. Evans syndrome: Result of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol 1995, 17:290-295.
103. Hall S., McCormick J.L., Greipp P.R., et al. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med 1985, 102:325-328.
104. Siegel R.S., Rae J.L., Barth S., et al. Platelet survival and turnover: Important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989, 30:206-212.
105. Najean Y., Rain D., duFour V. The sequestration of 111-In-labelled autologous platelets and the efficiency of splenectomy. Nouv Rev Franc d'Hematol 1991, 33:449-450.
106. Schwartz J., Eldor A., Gillis S., et al. Long term follow-up of splenectomy for immune thrombocytopenic purpura (ITP). Am J Hematol 2003, 72:94-98.
107. Portielje J.E.A., Westendorp R.G.J., Kluin-Nelemans H.C., et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001, 97:2549-2554.
108. Harold K.L., Schlinkert R.T., Mann D.K., et al. Long-term results of laparoscopic splenectomy for immune thrombocytopenic purpura. Mayo Clin Proc 1999, 74:37-39.
109. Marcaccio M.J. Laparoscopic vs. open splenectomy. Sem Hematol 2000, 37:267-274.
110. Pai V.B., Nahata M.C. Duration of penicillin prophylaxis in sickle cell anemia: Issues and controversy. Pharmacotherapy 2000, 20:110-117.
111. Ahn Y.S., Horstman L.L., Jy W., et al. Vascular dementia in patients with immune thrombocytopenic purpura. Thromb Res 2002, 107:337-344.
112. Berchtold P., McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989, 74:2309-2317.
113. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997, 126:307-314.
114. Bussel J.B. Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients. Sem Oncol 2000, 27(suppl 12):91-98.
115. Reiner A., Gernsheimer T., Slichter S.J. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995, 85:351-358.
116. Figueroa M., Gehlsen J., Hammond D., et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993, 328:1226-1229.
117. Rocha R., Horstman L., Ahn Y.S., et al. Danazol therapy for cyclic thrombocytopenia. Am J Hematol 1991, 36:140-143.
118. Moake J.L., Rudy C.K., Troll J.H., et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985, 20:73-79.
119. Huhn R.D., Fogarty P.F., Nakamura R., et al. High-dose cyclophosphamide with autologous lymphocytedepleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003, 101:71-77.